Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
News and Events

Featured Stories

Hot information:
Top 10 Global Clinical Research Organizations in 2021| Top 10 Global CDMO Enterprises| Preclinical Drug Development Process
Aug 01,2022
ADC, precision and deep cultivation for targeted drug delivery
Antibody conjugate (ADC) is the focus of tumor therapy research in recent years. Because of its good targeting and obvious clinical efficacy, ADC has become the frontier of antibody drug research and development and is one of the strategic focuses of new drug research and development in China.
More
ADC, precision and deep cultivation for targeted drug delivery
Aug 01,2022
CGeneTech's Class 1 innovative drug CGT-9475 has achieved dual application and approval in China and the US with the help of Medicilon's one-stop preclinical pharmaceutical R&D service platform
On July 22, CGT-9475, a new generation of ALK inhibitor independently developed by CGeneTech (Suzhou, China) Co., Ltd. (CGeneTech), was approved by the US Food and Drug Administration (FDA) to enter the clinical trial.
More
CGeneTech's Class 1 innovative drug CGT-9475 has achieved dual application and approval in China and the US with the help of Medicilon's one-stop preclinical pharmaceutical R&D service platform
Jun 10,2022
Empowering nucleic acid drug therapy to meet the third wave of new drug research and development
The global epidemic of COVID-19 has made mRNA vaccines a great success in the market, promoted the research and development of nucleic acid drugs and the development and maturity of technical platforms, and demonstrated its potential and energy to the global pharmaceutical industry, becoming part of the third biotechnology revolution.
More
Empowering nucleic acid drug therapy to meet the third wave of new drug research and development
May 30,2022
Accurate model, holding the key to unlocking the treatment of autoimmune diseases
We have constructed a variety of mature animal models of autoimmune diseases, which can comprehensively reflect and evaluate the pathological and pharmacodynamic characteristics of various diseases, especially experienced of the pharmacodynamic evaluation ofcurrent popular JAKs inhibitors.
More
Accurate model, holding the key to unlocking the treatment of autoimmune diseases
May 07,2022
New Drug Discovery and Development
Drug Discovery Period >> Drug Development and Registration Period >> Drug Release to Market Drug Marketing and Product Line Expansion
More
New Drug Discovery and Development
May 07,2022
Overview of the Drug Discovery Process
The steps of drug discovery can be simply summarized as disease→target→hit→lead→candidate→drug.
More
Overview of the Drug Discovery Process
Apr 22,2022
The Special Effects Channel Leading to the Fight Against the New Crown - Paxlovid
Pfizer's Paxlovid (Paxlovid) oral drug for the new crown will be launched for the first time at the end of 2021. Until February this year, the official website of China's State Food and Drug Administration released the important news of the drug's import registration, which will be included in the medical insurance payment system shortly. The time was sensational.
More
The Special Effects Channel Leading to the Fight Against the New Crown - Paxlovid
Feb 09,2022
Stability Studies of Pharmaceuticals
Medicilon has extensive experience of performing stability studies on active pharmaceutical ingredients, early prototype formulations and finished dosage forms. Stability testing is performed according to FDA-ICH guidelines, client approved protocols and standard operating procedures.
More
Stability Studies of Pharmaceuticals
Feb 09,2022
Pharmaceutical Preformulation Studies
Medicilon offers a full spectrum of Pharmaceutical Preformulation testing capabilities. Medicilon has wide knowledge in pharmaceutical preformulation studies.
More
Pharmaceutical Preformulation Studies
Jan 21,2022
Indirect Fluorescent Antibody Test
Indirect Fluorescent Antibody is to use a specific antibody to react with the corresponding antigen in the specimen, and then use a fluorescein-labeled secondary antibody (anti-antibody) to bind to the primary antibody in the antigen-antibody complex, and observe the specificity under a fluorescence microscope after washing.
More
Indirect Fluorescent Antibody Test